Gideon Bosker, MD

Review

Pharmacoinvasive Management of Acute Coronary Syndrome in the Setting of Percutaneous Coronary Intervention: Evidence-Based, Sit

08/01/2008

Deepak L. Bhatt , MD, MPH, FACC, FAHA, FESC, MSCAI;

Gideon Bosker , MD;

Gary L. Schaer , MD, FACC, FSCAI;

Dean J. Kereiakes , MD, FACC, FSCAI;

Jose G. Diez , MD;

Edward T.A. Fry , MD;

James J. Ferguson III, MD;

James P. Zidar , MD;

Glenn N. Levine , MD;

James E. Tcheng , MD;

Over the past decade, impressive reductions in mortality, reinfarction and length of hospital stay have been reported in large-scale studies of patients with acute coronary syndrome (ACS). Despite these advances, substantial challenges remain...

Over the past decade, impressive...

08/01/2008

Journal of Invasive Cardiology

Review

Pharmacoinvasive Management of Acute Coronary Syndrome in the Setting of Percutaneous Coronary Intervention: Evidence-Based, Sit

08/01/2008

Dean J. Kereiakes , MD, FACC, FSCAI;

Jose G. Diez , MD;

Edward T.A. Fry , MD;

James J. Ferguson III, MD;

James P. Zidar , MD;

Glenn N. Levine , MD;

James E. Tcheng , MD;

Deepak L. Bhatt , MD, MPH, FACC, FAHA, FESC, MSCAI;

Gideon Bosker , MD;

Gary L. Schaer , MD, FACC, FSCAI;

Part II of III - Continued TABLE 3 KEY (continued) 2) Unfractionated heparin(UFH) can be used as an alternative to enoxaparin. If UFH is used in the setting of PCI, activated clotting time (ACT) should be followed to achieve an appropriate...

Part II of III -...

08/01/2008

Journal of Invasive Cardiology

Review

Pharmacoinvasive Management of Acute Coronary Syndrome in the Setting of Percutaneous Coronary Intervention: Evidence-Based, Sit

08/01/2008

James J. Ferguson III, MD;

James P. Zidar , MD;

Glenn N. Levine , MD;

James E. Tcheng , MD;

Deepak L. Bhatt , MD, MPH, FACC, FAHA, FESC, MSCAI;

Gideon Bosker , MD;

Gary L. Schaer , MD, FACC, FSCAI;

Dean J. Kereiakes , MD, FACC, FSCAI;

Jose G. Diez , MD;

Edward T.A. Fry , MD;

A total of 5,225 patients were enrolled in the PARAGON B trial. Among these patients, the type of heparin used was known in 5,200 (99.5%). The median duration of therapy was 72.8 hours for UFH and 79.7 hours for LMWH. LMWH was used in about...

A total of 5,225 patients were...

08/01/2008

Journal of Invasive Cardiology